Tempest Therapeutics, Inc. Payments of Financing Costs
Tempest Therapeutics, Inc. (TPST) reported Payments of Financing Costs of $197.00 thousand for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2020-11-09
- Tempest Therapeutics, Inc. payments of financing costs for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- Tempest Therapeutics, Inc. payments of financing costs for the quarter ending 2020-06-30 was $0.00, a 100.00% decline year-over-year.
- Tempest Therapeutics, Inc. payments of financing costs for the quarter ending 2020-03-31 was $197.00K, a 1213.33% increase year-over-year.
- Tempest Therapeutics, Inc. payments of financing costs for the quarter ending 2019-12-31 was -$245.00K, a 140.16% decline year-over-year.
- Tempest Therapeutics, Inc. payments of financing costs for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- Tempest Therapeutics, Inc. payments of financing costs for fiscal 2018 was $1.35M, a 219.39% increase from fiscal 2017.
- Tempest Therapeutics, Inc. payments of financing costs for fiscal 2017 was $423.00K.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 6 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month |
|---|---|---|---|---|
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | $197.00K 10-Q · filed 2020-11-09 | -$48.00K derived: sum of 4 quarters · filed 2020-11-09 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $197.00K 10-Q · filed 2020-08-10 | -$48.00K derived: sum of 3 quarters · filed 2020-08-10 | $35.00K derived: sum of 4 quarters · filed 2020-11-09 |
| 2020-03-31 | $197.00K 10-Q · filed 2020-05-08 | -$48.00K derived: sum of 2 quarters · filed 2020-05-08 | $35.00K derived: sum of 3 quarters · filed 2020-11-09 | $182.00K derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-12-31 | -$245.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | -$162.00K derived: sum of 2 quarters · filed 2020-11-09 | -$15.00K derived: sum of 3 quarters · filed 2020-11-09 | $0.00 10-K · filed 2020-03-11 |
| 2019-09-30 | $83.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $230.00K derived: sum of 2 quarters · filed 2020-11-09 | $245.00K 10-Q · filed 2020-11-09 | $855.00K derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $147.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $162.00K 10-Q · filed 2020-08-10 | $772.00K derived: sum of 3 quarters · filed 2020-08-10 | $1.03M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $15.00K 10-Q · filed 2020-05-08 | $625.00K derived: sum of 2 quarters · filed 2020-05-08 | $884.00K derived: sum of 3 quarters · filed 2020-05-08 | |
| 2018-12-31 | $610.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $869.00K derived: sum of 2 quarters · filed 2020-03-11 | $1.35M 10-K · filed 2020-03-11 | |
| 2018-09-30 | $259.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $741.00K 10-Q · filed 2019-11-13 | ||
| 2018-06-30 | $482.00K 10-Q · filed 2019-08-12 | |||
| 2017-12-31 | $423.00K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |